National Guideline Clearinghouse | Guidelines of care for the management of atopic dermatitis. Section 1. Diagnosis and assessment of atopic dermatitis.
American Academy of Dermatology
Guideline Title
Guidelines of care for the management of atopic dermatitis. Section 1. Diagnosis and assessment of atopic dermatitis.
Bibliographic Source(s)
Eichenfield LF, Tom WL, Chamlin SL, Feldman SR, Hanifin JM, Simpson EL, Berger TG, Bergman JN, Cohen DE, Cooper KD, Cordoro KM, Davis DM, Krol A, Margolis DJ, Paller AS, Schwarzenberger K, Silverman RA, Williams HC, Elmets CA, Block J, Harrod CG, Smith Begolka W, Sidbury R. Guidelines of care for the management of atopic dermatitis. Section 1. Diagnosis and assessment of atopic dermatitis. J Am Acad Dermatol. 2014 Feb;70(2):338-51. [176 references] PubMed  |
Guideline Status
This is the current release of the guideline.
This guideline updates a previous version: Hanifin JM, Cooper KD, Ho VC, Kang S, Krafchik BR, Margolis DJ, Schachner LA, Sidbury R, Whitmore SE, Sieck CK, Van Voorhees AS. Guidelines of care for atopic dermatitis. J Am Acad Dermatol. 2004 Mar;50(3):391-404. [212 references]
J Am Acad Dermatol. 2014 Feb;70(2):338-51. doi: 10.1016/j.jaad.2013.10.010. Epub 2013 Nov 27.
Guidelines of care for the management of atopic dermatitis: section 1. Diagnosis and assessment of atopic dermatitis.
Eichenfield LF1, Tom WL1, Chamlin SL2, Feldman SR3, Hanifin JM4, Simpson EL4, Berger TG5, Bergman JN6, Cohen DE7, Cooper KD8, Cordoro KM5, Davis DM9, Krol A4, Margolis DJ10, Paller AS11, Schwarzenberger K12, Silverman RA13, Williams HC14, Elmets CA15, Block J16, Harrod CG17, Smith Begolka W18,Sidbury R19.
Abstract
Atopic dermatitis (AD) is a chronic, pruritic, inflammatory dermatosis that affects up to 25% of children and 2% to 3% of adults. This guideline addresses important clinical questions that arise in the management and care of AD, providing updated and expanded recommendations based on the available evidence. In this first of 4 sections, methods for the diagnosis and monitoring of disease, outcomes measures for assessment, and common clinical associations that affect patients with AD are discussed. Known risk factors for the development of disease are also reviewed.
Copyright © 2013 American Academy of Dermatology, Inc. Published by Mosby, Inc. All rights reserved.
KEYWORDS:
AAD; AD; ADHD; American Academy of Dermatology; CDLQI; Children's Dermatology Life Quality Index; DFI; DLQI; Dermatitis Family Impact; Dermatology Life Quality Index; EASI; Eczema Area and Severity Index; FLG; GREAT; Global Resource for Eczema Trials; IGA; IL; ISAAC; IgE; International Study of Asthma and Allergies in Childhood; Investigator's Global Assessment; MDC; POEM; Patient-Oriented Eczema Measure; SASSAD; SCORAD; SCORing Atopic Dermatitis; SORT; Six Area, Six Sign Atopic Dermatitis; TARC; TISS; Three-Item Severity Scale; UK; United Kingdom; assessment scales; atopic dermatitis; attention deficit hyperactivity disorder; biomarkers; clinical associations; criteria; diagnosis; filaggrin; immunoglobulin E; interleukin; macrophage-derived chemoattractant; risk factors; strength of recommendation taxonomy; thymus and activation-regulated chemokine
- PMID:
- 24290431
- [PubMed - indexed for MEDLINE]
No hay comentarios:
Publicar un comentario